AXIM BIOTECHNOLOGIES, INC. (AXIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 300K 600K 900K FY11: 10K FY12: 43.3K FY13: 21.7K FY14: 0 FY15: 49.1K FY16: 47.1K FY17: 47.6K FY18: 195.6K FY19: 799.5K FY20: 0 FY21: 60.5K FY22: 8.9K FY23: 39.5K FY11 FY13 FY15 FY17 FY19 FY21 FY23

Gross Profit Annual

-140K -70K 0 70K 140K 210K FY14: 0 FY15: -1.2K FY16: -107.1K FY17: 4.7K FY18: 187.1K FY19: 0 FY20: 0 FY14 FY15 FY16 FY17 FY18 FY19 FY20

Operating Income Annual

-15M -10M -5M 0 5M 10M 15M FY14: -505.7K FY15: -10M FY16: -3.8M FY17: -3.1M FY18: -5M FY19: -3.1M FY20: -4.9M FY21: -14M FY22: -4.7M FY23: -2.8M FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23

Net Income Annual

-18M -12M -6M 0 6M 12M 18M FY11: -2.8K FY12: -14.9K FY13: -89.2K FY14: -582.9K FY15: -10.1M FY16: -5.8M FY17: -4.2M FY18: -6.8M FY19: -6.4M FY20: -6.4M FY21: -16M FY22: -6.2M FY23: -8.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23

Cost of Revenue Annual

0 60K 120K 180K FY16: 154.1K FY17: 42.9K FY18: 8.5K FY19: 0 FY20: 0 FY16 FY17 FY18 FY19 FY20

Operating Cash Flow Annual

-6M -4M -2M 0 2M 4M 6M FY11: 4K FY12: 21.1K FY13: -33K FY14: -339K FY15: -1.5M FY16: -1.3M FY17: -3.1M FY18: -4.8M FY19: -5M FY20: -3.2M FY21: -2.5M FY22: -2M FY23: -1M FY11 FY13 FY15 FY17 FY19 FY21 FY23

Free Cash Flow Annual

-4.5M -3M -1.5M 0 1.5M 3M 4.5M FY14: -339K FY15: -1.6M FY16: -1.3M FY20: -3.3M FY21: -2.5M FY22: -2.1M FY23: -1M FY14 FY15 FY16 FY20 FY21 FY22 FY23

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 8M 16M 24M FY11: 23.3M FY11

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q4 '11: 0.00 Q1 '12: 0.00 Q2 '12: 0.00 Q3 '12: 0.00 Q4 '13: 0.00 Q1 '14: 0.00 Q2 '14: 0.00 Q3 '14: 0.00 Q4 '14: -0.01 Q1 '15: -0.03 Q2 '15: -0.07 Q3 '15: -0.11 Q4 '15: -0.27 Q1 '16: -0.27 Q2 '16: -0.28 Q3 '16: -0.31 Q4 '16: -0.16 Q1 '17: -0.15 Q2 '17: -0.11 Q3 '17: -0.07 Q4 '17: -0.08 Q1 '18: -0.12 Q2 '18: -0.14 Q3 '18: -0.13 Q4 '18: -0.12 Q1 '19: -0.11 Q2 '19: -0.11 Q3 '19: -0.10 Q4 '19: -0.10 Q1 '20: -0.09 Q2 '20: -0.06 Q3 '20: -0.07 Q4 '20: -0.07 Q1 '21: -0.05 Q2 '21: -0.08 Q3 '21: -0.09 Q4 '21: 0.11 Q1 '22: 0.11 Q2 '22: 0.13 Q3 '22: 0.15 Q4 '22: -0.04 Q1 '23: -0.04 Q2 '23: -0.05 Q3 '23: -0.04 Q4 '23: -0.05 Q1 '24: -0.03 Q2 '24: -0.02 Q4 '13 Q2 '15 Q4 '16 Q2 '18 Q4 '19 Q2 '21 Q4 '22 Q2 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.